Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

completed250%
terminated125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completed

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

NCT07379788
terminatedphase_2

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

NCT04906213
completednot_applicable

Empagliflozin in Heart Failure Dialysis Patients

NCT05967156
recruiting

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

NCT06284850

Clinical Trials (4)

Showing 4 of 4 trials
NCT07379788

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Completed
NCT04906213Phase 2

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Terminated
NCT05967156Not Applicable

Empagliflozin in Heart Failure Dialysis Patients

Completed
NCT06284850

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4